KR20190008225A - 화학적 신경차단으로 인한 부작용의 치료 - Google Patents

화학적 신경차단으로 인한 부작용의 치료 Download PDF

Info

Publication number
KR20190008225A
KR20190008225A KR1020187032859A KR20187032859A KR20190008225A KR 20190008225 A KR20190008225 A KR 20190008225A KR 1020187032859 A KR1020187032859 A KR 1020187032859A KR 20187032859 A KR20187032859 A KR 20187032859A KR 20190008225 A KR20190008225 A KR 20190008225A
Authority
KR
South Korea
Prior art keywords
alkyl
anticholinesterase
composition
muscle
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187032859A
Other languages
English (en)
Korean (ko)
Inventor
메리 가드너
Original Assignee
델노바 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 델노바 인코퍼레이티드 filed Critical 델노바 인코퍼레이티드
Priority to KR1020227011091A priority Critical patent/KR20220063197A/ko
Publication of KR20190008225A publication Critical patent/KR20190008225A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
KR1020187032859A 2016-05-13 2017-05-15 화학적 신경차단으로 인한 부작용의 치료 Ceased KR20190008225A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227011091A KR20220063197A (ko) 2016-05-13 2017-05-15 화학적 신경차단으로 인한 부작용의 치료

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662336344P 2016-05-13 2016-05-13
US62/336,344 2016-05-13
PCT/US2017/032636 WO2017197382A1 (en) 2016-05-13 2017-05-15 Treating of side-effects resulting from chemodenervation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227011091A Division KR20220063197A (ko) 2016-05-13 2017-05-15 화학적 신경차단으로 인한 부작용의 치료

Publications (1)

Publication Number Publication Date
KR20190008225A true KR20190008225A (ko) 2019-01-23

Family

ID=60266879

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187032859A Ceased KR20190008225A (ko) 2016-05-13 2017-05-15 화학적 신경차단으로 인한 부작용의 치료
KR1020227011091A Ceased KR20220063197A (ko) 2016-05-13 2017-05-15 화학적 신경차단으로 인한 부작용의 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227011091A Ceased KR20220063197A (ko) 2016-05-13 2017-05-15 화학적 신경차단으로 인한 부작용의 치료

Country Status (10)

Country Link
US (2) US11129822B2 (https=)
EP (1) EP3454855B1 (https=)
JP (4) JP2019515052A (https=)
KR (2) KR20190008225A (https=)
CN (2) CN109414434A (https=)
AU (2) AU2017263850A1 (https=)
BR (1) BR112018073388A2 (https=)
CA (1) CA3023408A1 (https=)
IL (1) IL262916A (https=)
WO (1) WO2017197382A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502981A (ja) * 2017-11-15 2021-02-04 デルノバ・インコーポレイテッドＤｅｌＮｏｖａ，Ｉｎｃ． ボツリヌス治療の副作用の処置
WO2025226839A2 (en) * 2024-04-23 2025-10-30 New York University Auf1 compositions and methods for promoting generation of neuromuscular junctions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925856A (en) * 1987-07-28 1990-05-15 Sri International Aldoxime-substituted imidazolium derivatives useful in the treatment of poisoning by phosphorus-containing chemicals
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
EP0619814A1 (en) * 1991-12-31 1994-10-19 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
GB9410871D0 (en) * 1994-05-31 1994-07-20 Imperial College Modification of tetanus toxin for use as a transport protein
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6759552B2 (en) * 2002-03-28 2004-07-06 Council Of Scientific And Industrial Research Compound as cholinesterase inhibitor and its isolation from fungus sporotrichum species
CN1260349C (zh) * 2003-04-29 2006-06-21 云南省微生物研究所 南宁链霉菌
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
US20080090808A1 (en) * 2006-10-17 2008-04-17 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
WO2009036235A2 (en) * 2007-09-12 2009-03-19 Virginia Tech Intellectual Properties, Inc. Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (ache)
CN101386818B (zh) * 2008-07-29 2011-01-19 中山大学 一种海洋真菌培养物的提取物及其制备方法和应用
JP5782439B2 (ja) * 2009-07-24 2015-09-24 リポテック, エセ.ア.Lipotec, S.A. 筋肉収縮を抑制する化合物
KR101067153B1 (ko) * 2009-10-16 2011-09-22 경상대학교산학협력단 뇌신경 세포 보호 활성 및 아세틸콜린에스테라제 저해 활성을 갖는 율피 추출물 및 그의 용도
CN102933200B (zh) 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
JP2014520148A (ja) * 2011-06-20 2014-08-21 セントルイス ユニバーシティ 治療のための神経筋接合部への標的化
CN103524515B (zh) * 2012-07-03 2016-07-06 浙江海正药业股份有限公司 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途
AU2013312240A1 (en) * 2012-09-10 2015-03-19 Ophirex Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
LT3157534T (lt) * 2014-06-19 2022-09-12 Attillaps Holdings Acetilcholinesterazės inhibitoriai, skirti dermatologinių būklių gydymui

Also Published As

Publication number Publication date
EP3454855B1 (en) 2023-12-20
JP2025108527A (ja) 2025-07-23
US20220175753A1 (en) 2022-06-09
AU2017263850A1 (en) 2018-11-22
IL262916A (en) 2018-12-31
EP3454855A4 (en) 2019-12-25
CN109414434A (zh) 2019-03-01
JP2024099644A (ja) 2024-07-25
JP2022088660A (ja) 2022-06-14
JP2019515052A (ja) 2019-06-06
CN119950719A (zh) 2025-05-09
CA3023408A1 (en) 2017-11-16
US20190183875A1 (en) 2019-06-20
AU2023201832A1 (en) 2023-04-27
WO2017197382A1 (en) 2017-11-16
US11129822B2 (en) 2021-09-28
EP3454855A1 (en) 2019-03-20
BR112018073388A2 (pt) 2019-07-02
KR20220063197A (ko) 2022-05-17

Similar Documents

Publication Publication Date Title
DE60128899T2 (de) Verwendung eines botulinumtoxins zur herstellung eines arzneimittels zur peripheren behandlung von schmerzen, die nicht mit muskelspasmen oder kopfschmerzen in verbindung stehen
JP2025108527A (ja) 化学的除神経から生じる副作用の処置
US6596756B1 (en) Treatment of fibromyalgia
JP2013505983A5 (https=)
CN102143687B (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途
DE69114470T2 (de) Komposition für die behandlung von augenschmerzen.
EP1864667B1 (en) Use of prodrugs for ocular intravitreous administration
CN101573130A (zh) 表皮生长因子用于在糖尿病性神经病中外周神经的形态功能恢复的用途
CZ284441B6 (cs) Použití 4-aminopyridinu k výrobě léčiva pro léčbu neurologického stavu
WO2025054397A9 (en) Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
Skovira et al. Neuropharmacological specificity of brain structures involved in soman-induced seizures
JP2023055802A (ja) ダントロレンを使用して神経薬暴露を治療する方法
CN106074660A (zh) 乳香和没药在制备防治神经病理性痛疾病药物中的应用
JP2016514726A (ja) 化学療法誘発末梢神経障害の処置
Benabid et al. Might deep brain stimulation of the subthalamic nucleus be neuroprotective in patients with Parkinson’s disease?
Jabbari Botulinum Toxin Therapy for Neuropathic Pain (NP)
JP2021502981A (ja) ボツリヌス治療の副作用の処置
RU2817851C2 (ru) Способы применения дантролена для лечения воздействия нервно-паралитического вещества
US20050059709A1 (en) Treatment of a neuropathy with rapid release aminopyridine
EP2453890B1 (en) Compositions comprising a cholinesterase inhibitor for treating cognitive disorders
US20050192321A1 (en) Treatment of neuropathy with rapid release aminopyridine

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181113

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200507

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210601

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220103

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210601

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220404

PJ0201 Trial against decision of rejection

Patent event date: 20220404

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20220103

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2022101000762

Request date: 20220404

J301 Trial decision

Free format text: TRIAL NUMBER: 2022101000762; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20220404

Effective date: 20230810

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20230810

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20220404

Decision date: 20230810

Appeal identifier: 2022101000762